Generalised Pustular Psoriasis (von Zumbusch type) following renal Transplantation. Report of a case and review of the literature by Vougas, V. et al.
89
Generalised Pustular Psoriasis (von 
Zumbusch type) following renal 
Transplantation. Report of a case  
and review of the literature
Vougas V1, Dedemadi G1, Noutsis K2, Apostolou Th1,  
Pantelidaki C3, Drakopoulos S1
A B S t R A C t
Generalized pustular psoriasis appears as an uncommon variant form of psoriasis 
consisting of widespread pustules on an erythematous background (von Zumbusch). 
A 39-year-old male patient with a history of plaque psoriasis since the age of nine who 
had an acute onset of generalized pustular psoriasis twelve days after he underwent 
renal transplantation is presented. Despite administered immunosuppression for 
transplantation, the addition of cyclosporine A and methotrexate did not reverse 
the ongoing process of disease and the patient died on the 57th post-transplant day 
due to multiorgan failure following severe bone marrow suppression.
I N t R O D U C t I O N
Generalized pustular psoriasis is an uncommon skin disease with resistance to 
medical treatment causing diagnostic pitfalls. Patients suffering from the disease are 
presented with an extensive area of erythematous background and multiple small 
pustules. Severity of disease and response to medical treatment can vary [1]. The 
activation of T-lymphocytes and tumour necrosis factor alpha (TNF-a) determines 
the type and severity of manifestation [2]. Acute generalized type (von Zumbusch 
variant) is associated with fever and toxicity.
The disease is unusual in Great Britain, while the prevalence in Japan is 7.46 per 
million of population. Both genders are affected equally. Etiology has not been completely 
clarified. Although many factors can be considered as triggering eruption of disease, 
the most important seems to be a sudden withdrawal of steroids after systematic use 
and drugs including salicylates, lithium, and penicillin. Other factors such as infec-
tions of the upper respiratory system, pregnancy, exposure to sunlight, phototherapy, 
jaundice, hypocalcemia, and hypoparathyroidism have also been incriminated [2]. 
Generalized pustular psoriasis rarely appears in patients after organ transplantation, 
with the exception of only two cases so far reported in the literature [3,4].
C A S e  R e p O R t
The case of a 39-year-old male patient with a 20-year history of chronic kidney 
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disease of unknown etiology, on regular hemodialysis for the 
last nine years is presented. The patient suffered from tetralogy 
of Fallot treated successfully with surgery at the age of eight. 
In 1993, after a transient episode of collapse, a pacemaker was 
implanted because of a sinoventricular block. In 2001, he had a 
mild cerebrovascular attack which resulted in minor left sided 
hemiplegia. A history of allergy to non-steroidal anti-inflam-
matory drugs and vancomycin was reported. Since childhood, 
he suffered from mild psoriasis receiving local corticosteroids 
and moisturizers. Skin lesions had seasonal accentuation with 
aggravation in spring and remission during summer. Being 
on the waiting list for a renal transplant, he underwent total 
thyroidectomy and parathyroidectomy due to multinodular 
goiter and hyperparathyroidism.
A cadaveric renal transplantation was performed in April 
2006, using a HLA A2 and DR14 compatible (4 mismatches) 
graft. The patient received induction treatment with Daclizumab 
(1mg/kg/day) and a triple immunosuppressive regimen with 
Tacrolimus (0.1mg/kg/day), Mycophenolate Mofetil (2gr/day), 
and methylprednisolone according to protocol (1gr IV during 
surgery followed by prednisolone of 200 mg on the 1st post-
operative day, which was tapered to oral prednisolone of 20 
mg/day within 2 weeks and to 10mg/day within a month). Beside 
immunosuppression, the patient continued on cefotaxime, 
ciprofloxacin, erythropoietin, protein pump inhibitors, and 
furosemide during his postoperative course.
Due to delayed graft function he remained on hemodialysis. 
On the 6th postoperative day, he developed trunk erythematous 
lesions and local corticoid treatment (Fluticasone) was applied 
(Picture 1). Twelve days postoperatively, skin lesions aggravated, 
expanding to the whole trunk and extremities while multiple 
clusters of nonfollicular, superficial 2 to 3mm pustules appeared 
(Picture 2). A gram staining and pus culture from pustules did 
not reveal any microorganisms. After reducing prednisolone 
to 10mg/day, on the 30th postoperative day, the patient ex-
hibited a dramatic deterioration of skin lesions, consisting of 
a widespread and generalized body pustular exanthema. A 
skin biopsy revealed pustular psoriasis of the von Zumbusch 
variant, with eosinophilic infiltrate indicative of drug toxicity 
(Picture 3 and 4). Renal graft biopsy confirmed signs of acute 
rejection, treated with methylprednisolone, 500mg for 3 days. 
On the 37th postoperative day, the patient became toxic with 
increasing pyrexia and reduced urinary output. Mycophenolate 
Mofetil and Daclizumab were discontinued; Tacrolimus was 
substituted by Cyclosporine A (3.0mg/kg/day), with an increase 
of steroids to 30mg/day. As skin lesions were extending to 
the whole body surface, becoming life threatening, 50mg of 
methotrexate were administered on days 39 and 46 postop-
eratively. The patient developed sepsis, a body temperature of 
39.5 °C, pancytopenia (WBC: 0.320×103/nl, Hct: 25.1%, Hb: 
8.4g/dl, PLT: 29×103/nl), signs of disseminated intravascular 
coagulation, oliguria (400ml/day), and respiratory distress. Red 
blood cells and platelets transfusions as well as glycosylated 
recombinant form of human granulocyte colony stimulating 
factor r-HuG-CSF were also added. On the 57th postoperative 
day, the patient died from multi-organ failure.
D I S C U S S I O N
Psoriasis is a chronic, inflammatory skin disease affecting 
approximately 2% of Caucasians, but it is rare among Japanese, 
Eskimos, West Africans, and North American blacks and very 
uncommon in North American and South American natives. 
The cause for these variations is likely to be both genetic and 
environmental [5]. There is a considerable epidemiologic 
verification that genetic factors determine the pathogenesis 
of psoriasis. The disease is multifactorial in origin and has a 
pICtURe 1. Generalized eruption with multiple small pus-
tules.
pICtURe 2. Generalized pustular psoriasis of the body and 
upper extremities.
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multigenetic inheritance [6].
Pustular psoriasis is an uncommon variant of psoriasis 
and may be classified into several types depending on the 
clinical course: acute, subacute or chronic. The acute type 
(von Zumbusch variant) occurs with erythematous lesions 
producing burning sensation and may be associated with 
upper respiratory system or other systemic infections. High 
temperature appears suddenly with shiver and chills. The 
patient experiences constitutional signs and symptoms. For-
mation of multiple small pustules on an erythematous back-
ground occurs in a generalized pattern. In the acute type, 
the pustules often become confluent to form lakes of pus [7]. 
Sometimes the disease is followed by pulmonary capillary 
leakage, pulmonary emphysema, jaundice, or renal failure 
due to hypoproteinemia and hypocalcaemia [8]. In the more 
common subacute and chronic types, the patients appear to 
have only skin symptoms [9].
No radical treatment is available so far, therefore, aim 
of treatment is improvement of patient’s quality of life [10]. 
Lately many authors have mentioned the benefit of calcineurin 
inhibitors to treat psoriasis [11-13]. Cyclosporine A inhibits 
T- lymphocytes and affects the function of phospholipase Α 
and the activation of interleukin 1 and 2, via its action against 
calcineurin, factors determinant for psoriasis [1,14]. There is 
strong evidence to support administration of Cyclosporine A 
which is considered the most effective and safe drug for treating 
severe psoriasis [15]. Some authors report a relapse of disease 
after withdrawal of Cyclosporine A [16-18].
Medical treatment with retinoids includes natural retinoids, 
vitamin A, and its active derivatives. The mechanism of action 
of retinoids in psoriasis is not completely understood. It has 
been considered that retinoids contribute to improvement of 
symptoms by normalizing keratinisation and proliferation of 
epidermal cells. They also control the production of cytokines 
(TNFa, IL-1 and IL-6) [19,20].
Methotrexate has also been proposed as a treatment of 
severe psoriasis. It inhibits the differentiation and prolifera-
tion of epidermis. It affects the immune system by inhibiting 
macrophages and neutrophils, as well as T and B lymphocytes 
[21]. Due to numerous side effects and toxicity, methotrexate 
should be used cautiously especially in patients with renal 
failure [22]. In our patient, methotrexate administration was 
necessary, despite delayed graft function, due to deterioration 
of skin disease and the above mentioned given treatment was 
ineffective. Whether sepsis and multiorgan failure was related 
to pustular psoriasis per se or to over-immunosuppression, this 
was not elucidated upon.
A novel concept in the treatment of pustular psoriasis may 
be biologic therapies, using anti-TNF-alpha agents, designed to 
selectively interfere with the immune mechanisms that induce 
psoriasis. TNF-alpha antibodies (infliximab) and TNF-alpha 
receptors (etanercept) combine a rapid onset of action in the 
initiation therapy with a lower risk for severe adverse events 
[23,24]. The long term safety of all these agents has not yet 
been established.
Other anti-inflammatory and immunosuppressive drugs, 
such as corticosteroids, are used for pustular psoriasis, particu-
larly early on in the acute stage. Reduction or withdrawal of 
corticosteroids may lead to relapse of disease [10]. They could 
be administered in combination with retinoids (Acitretin), 
Cyclosporine A, or Methotrexate during the acute stage.
Local treatment includes corticosteroid compounds and 
products of vitamin D3.
All these alternatives can be used for treating pustular pso-
riasis either alone or in combination. While standard systemic 
therapy is effective in the short term, unpredictable toxicity 
and gradual decline in efficacy could complicate a long term 
use. Rotating or combining different treatment modalities 
pICtURe 3 & pICtURe 4. Psoriasis. Psoriasiform epidermal hyperplasia with spongiform pustules of Kogoj. H.E. X 200.
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mitigates against these problems, but for a significant group 
of patients with severe disease adequate control is impossi-
ble or achieved only with actual or high risk of drug toxicity 
and consequent morbidity. It is remarkable that in our case, 
Cyclosporine Α, an immunosuppressive agent, drug of choice 
for transplantation and main treatment for psoriasis was not 
able to prevent rapid ongoing process of disease. Very good 
results are reported after administration of combined therapy 
including Cyclosporine Α and Methotrexate in twenty patients 
with severe psoriasis without renal disease [25].
The literature provides data on the incidence of patients 
with severe psoriasis and chronic renal failure as well as the 
potential beneficial outcome after hemodialysis or peritoneal 
dialysis [26, 27], but such an improvement was not noticed in 
our patient.
Pustular psoriasis is a rare disease among patients under-
going transplantation, with only two reports in the literature. 
The first concerns a patient with generalized pustular psoriasis 
after renal transplantation that was treated with combination 
therapy including cyclosporine Α and low dose methotrexate, 
while the recent report represents azathioprine as an alternative 
treatment for resistant psoriasis along with phototherapy and 
cyclosporine [3,4]. European guidelines for renal transplantation 
reported by the EBPG Expert Group in 2000 do not include 
psoriasis in the exclusion criteria [28]. With only two cases 
reported so far, as well as ours with a dismal prognosis, it is 
difficult to draw definite conclusions about whether patients 
with a history of psoriasis and chronic renal failure should be 
listed for transplantation.
R e F e R e N C e S
 1. Berth-Jones J. The use of ciclosporin in psoriasis. J Dermatolog 
Treat 2005; 16:258-277.
 2. Ohkawara A, yasuda H, Kobayashi H, Inaba y, et al. General-
ized pustular psoriasis in Japan; two distinct groups formed by 
differences in symptoms and genetic background. Acta Derm 
Venereol 1996; 76:68–71.
 3. Coulson IH, Evans CD, Holden CA. Generalized pustular 
psoriasis after renal transplantation--failure to suppress with 
cyclosporin A. Clin Exp Dermatol 1988; 13:416-417.
 4. Kaaroud H, Béji S, Jebali A, Ben Hamida F, et al. Pustular 
psoriasis after renal transplantation. Transplant Proc 2007; 
39:1130-1131.
 5. Giardina E, Sinibaldi C, Novelli G. Mapping the future of 
common diseases: lessons from psoriasis. Front Biosci 2007; 
12:1563-1573.
 6. Pasic A, Grahovac B, Lipozencic J, Kastelan M, et al. The genetics 
of psoriasis. Acta Dermatovenerol Croat 2004; 12:18-25.
 7. Zelickson BD, Muller SA. Generalized pustular psoriasis. A 
review of 63 cases. Arch Dermatol 1991; 127:1339–1345.
 8. Sadeh JS, Rudikoff D, Gordon ML, Bowden J, et al. Pustular 
and erythrodermic psoriasis complicated by acute respiratory 
distress syndrome. Arch Dermatol 1997; 133:747–750.
 9. Baker H (1985) Generalized pustular psoriasis. In: Roenigk 
HH Jr, Maibach HI (eds). Psoriasis. Marcel Dekker, New york, 
1985:15–33.
 10. umezawa y, Ozawa A, Kawasima T, Shimizu H, et al. 
Therapeutic guidelines for the treatment of generalized pustular 
psoriasis (GPP) based on a proposed classification of disease 
severity. Arch Dermatol Res 2003; 295:Supp1:S43–54.
 11. Sarzi-Puttini P, Cazzola M, Panni B, Turiel M, et al. Long-term 
safety and efficacy of low-dose cyclosporin A in severe psoriatic 
arthritis. Rheumatol Int 2002; 21: 234–238.
 12. De Rie MA, Meinardi MM, Bos JD. Analysis of side-effects 
of medium- and low-dose cyclosporin maintenance therapy in 
psoriasis. Br J Dermatol 1990; 123:347-353.
 13. Christophers E, Mrowietz u, Henneicke HH, Farber L, et al. 
Cyclosporine in psoriasis: a multicenter dose-finding study in 
severe plaque psoriasis. The German Multicenter Study. J Am 
Acad Dermatol 1992; 26:86-90.
 14. Bunjes D, Hardt C, Rollinghoff M, Wagner H. Cyclosporin A 
mediates immunosuppression of primary cytotoxic T cell responses 
by impairing the release of interleukin 1 and interleukin 2. Eur 
J Immunol 1981; 11:657-661.
 15. Berth-Jones J, Henderson CA, Munro CS, Rogers S, et al. Treat-
ment of psoriasis with intermittent short course cyclosporin (Ne-
oral).A multicenter study. Br J Dermatol 1997; 136: 527–530.
 16. Mahendran R, Grech C. Generalized pustular psoriasis follow-
ing a short course of cyclosporin (Neoral) Br J Dermatol 1998; 
139:934.
 17. Ho VC, Griffiths CE, Albrecht G, Vanaclocha F, et al. 
Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis 
unresponsive to topical therapy: a 1-year multicentre, randomized 
study. The PISCES Study Group. Br J Dermatol 1999; 141:283-
291.
 18. Heidenheim M, Oxholm A, da Cunha Bang F. Generalized 
pustular psoriasis in relation to withdrawal of cyclosporin A. Br 
J Dermatol 1990; 122:719.
 19. van de Kerkhof PC. update on retinoid therapy of psoriasis 
in: an update on the use of retinoids in dermatology. Dermatol 
Ther 2006; 19:252-263.
 20. yamauchi PS, Rizk D, Lowe NJ. Retinoid therapy for psoriasis. 
Dermatol Clin 2004; 22:467-476.
 21. Boffa MJ, Chalmers RJ. Methotrexate for psoriasis. Clin Exp 
Dermatol 1996; 21:399-408.
 22. Boey O, Van Hooland S, Woestenburg A, Van der Niepen 
P, et al. Methotrexate should not be used for patients with end-
stage kidney disease. Acta Clin Belg 2006; 61:166-169.
 23. Gisondi P, Girolomoni G. Biologic therapies in psoriasis: A new 
therapeutic approach. Autoimmun Rev 2007; 6:515-519. Epub 
2007.
 24. Weisenseel P, Prinz JC. Sequential use of infliximab and etaner-
cept in generalized pustular psoriasis. Cutis 2006; 78:197-199.
 25. Aydin F, Canturk T, Senturk N, Turanli Ay. Methotrexate and 
ciclosporin combination for the treatment of severe psoriasis. 
Clin Exp Dermatol 2006; 31:520-524.
 26. Nissenson AR, Rapaport M, Gordon A, Narins RG. Hemodialysis 
GENERALISED PuSTuLAR PSORIASIS (VON ZuMBuSCH TyPE) FOLLOWING RENAL TRANSPLANTATION
93
                                        
 28. EBPG (European Expert Group on Renal Transplantation); 
European Renal Association (ERA-EDTA); European 
Society for Organ Transplantation (ESOT). European best 
practice guidelines for renal transplantation (Part 1) Nephrol 
Dial Transplant 2000; 15 Suppl 7:1-85.
in the treatment of psoriasis. A controlled trial. Ann Intern Med 
1979; 91:218-220.
 27. Kramer P, Brunner FP, Brynger H, Chantler C, et al. Dialysis 
treatment and psoriasis in Europe. Clin Nephrol 1982; 18:62-
68.
